$CODX

Co-Diagnostics, Inc.

No enriched coverage for $CODX in the last 7 days.

No SEC Form 4 filings for $CODX in the last 30 days.

Med

Co-Diagnostics announces 1-for-30 reverse stock split By Investing.com

Co-Diagnostics, Inc. (NASDAQ:CODX) will effect a 1-for-30 reverse stock split on January 2, 2026, to meet Nasdaq's minimum bid price requirement. The company's stock has plummeted 69.44% year-to-date, and it reported significant revenue decline in Q3 2025. Despite financial challenges, Co-Diagnostics continues to expand its technology, recently securing an Australian patent for its Co-Dx PCR Pro platform and receiving a "Buy" rating from Maxim Group.

Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India

Co-Diagnostics, Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd., has been invited to participate in the 2nd Advanced TB Diagnostics Course in Chennai, India. This workshop, hosted by ICMR-NIRT and partners, focuses on addressing emerging needs in tuberculosis detection and research for the South-East Asian Region. The event features leading experts, national TB programs, and industry innovators discussing new technologies, cost-effectiveness, and policy development.

Inside a global effort to improve TB testing across South Asia this week

Co-Diagnostics' joint venture, CoSara Diagnostics, has been invited to participate in the 2nd Advanced TB Diagnostics Course in Chennai, India, scheduled for December 15-19, 2025. This workshop, organized with McGill International TB Centre and other global partners, aims to address emerging needs in tuberculosis detection and improve case-finding across the South-East Asian Region. Experts from various organizations, including WHO and The Gates Foundation, will contribute to discussions on diagnostics value chain, new technologies, and policy development.